Objective To systematically perform a meta-analysis of the association between different
comorbid conditions on safety (short-term outcomes) and effectiveness (long-term outcomes) in …

Aims Access to joint replacement is being restricted for patients with comorbidities in a number
of high-income countries. However, there is little evidence on the impact of comorbidities …

Background The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2006
and the 13-valent pneumococcal conjugate vaccine (PCV13) in 2010 in the UK. PCVs are …

Background Despite recommendations from the German Standing Committee on Vaccination
(STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This …

Background Acute otitis media (AOM) remains a common infection in children despite the
introduction of pneumococcal conjugate vaccines. This study estimated AOM incidence rates (…

Objective To estimate healthcare resource utilisation (HCRU) and costs associated with
pneumococcal disease (PD) in children aged ≤17 years in England from 2003–2019. Methods …

Background Pneumococcal disease is a leading cause of communicable disease morbidity
and mortality globally. We aimed to estimate invasive pneumococcal disease (IPD), …

This study assessed the incidence rate of all-cause pneumonia (ACP) and invasive
pneumococcal disease (IPD) and associated medical costs among individuals aged ≥16 in the …

Background Patients with inflammatory bowel disease are at increased risk of colorectal and
extra‐intestinal cancer. However, the overall cancer risk in patients with Crohn's disease (…

Background Since the introduction of higher valency pneumococcal conjugate vaccines in
2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in …